AhmedMofrehAlkalibyMDMSc., PhD., MRCS Edin and Glasg, FICO

Ophthalmology • Traverse City, MI

Retinal Disease

Vitreoretinal Consultant/Surgeon

Join to view full profile

Dr. Alkaliby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Alkaliby's full profile

Already have an account?

Office
860 E Front St
Traverse City, MI 49686
Is this information wrong?

Summary

Cataract and Vitreoretinal Surgery

Education & Training

University of California (Irvine)Fellowship, Surgical Retina and Vitreous, 2019 - 2021
Instituto de Microcirugía OcularMD, Retina, 2019 - 2019
University Retina and Macula associatesVisiting Fellow, Retina And Vitreous, 2018 - 2018
Tanta University Faculty of MedicineClass of 2011

Certifications & Licensure

IL State Medical License 2022 - 2026
OH State Medical License 2021 - 2025
MI State Medical License 2022 - 2025
CA State Medical License 2020 - 2022

Awards, Honors, & Recognition

Diamond Jubil Award APAO, 2021

Clinical Trials

Investigation of Therapeutic Efficacy and Safety of UMSCs for the Management of Retinitis Pigmentosa (RP) Start of enrollment: 2021 Feb 01
Recruiting
Phase 2
Stem Cells Therapy in Degenerative Diseases of the Retina Start of enrollment: 2018 Dec 13
Enrolling by invitation
Phase 1
Stem Cell Ophthalmology Treatment Study Start of enrollment: 2012 Aug 01
Enrolling by invitation
Not Applicable
Stem Cell Ophthalmology Treatment Study II Start of enrollment: 2016 Jan 01
Recruiting
Not Applicable
Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases. Start of enrollment: 2014 Feb 01
Completed
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy Start of enrollment: 2012 Jul 01
Active, not recruiting
Phase 1
Stem Cell Therapy for Outer Retinal Degenerations Start of enrollment: 2015 Aug 01
Completed
Phase 1, Phase 2
Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases Start of enrollment: 2015 May 01
Unknown status
Phase 1, Phase 2
Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells Start of enrollment: 2019 Apr 01
Completed
Phase 3
Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa Start of enrollment: 2021 Jun 01
Active, not recruiting
Phase 1
Join now to see all